Disposition of 5318 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 31.25 subject to Rule 16b-3

HDP1 Stock  EUR 21.10  0.45  2.18%   
Roughly 55% of Arrowhead Pharmaceuticals' stockholders are presently thinking to get in. The analysis of current outlook of investing in Arrowhead Pharmaceuticals suggests that some traders are interested regarding Arrowhead Pharmaceuticals' prospects. The current market sentiment, together with Arrowhead Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Arrowhead Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Arrowhead Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Arrowhead daily returns and investor perception about the current price of Arrowhead Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
  
Filed transaction by Arrowhead Pharmaceuticals Director, Officer Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3

Read at macroaxis.com
Disposition of 5318 common stock at 31.25 of Arrowhead Pharmaceuticals by Christopher Anzalone on 9th of June 2024. This event was filed by Arrowhead Pharmaceuticals with SEC on 2024-01-02. Statement of changes in beneficial ownership - SEC Form 4. Christopher Anzalone currently serves as ceo and president director, ceo of calando, ceo of tego, ceo of nantope, ceo of leonardo and ceo of ablaris therapeutics of Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Fundamental Analysis

We analyze Arrowhead Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Book Value Per Share

Book Value Per Share Comparative Analysis

Arrowhead Pharmaceuticals is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.

Arrowhead Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arrowhead Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics with similar companies.

Complementary Tools for Arrowhead Stock analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio